Three Hot Penny Stocks For Your Watchlist

| August 28, 2013 | 0 Comments

It’s an exciting time for Affirmative Insurance Holdings (AFFM), Celsius Holdings (CELH), and Prana Biotechnology (PRAN).  All three are hot penny stocks that have made huge gains in the past few weeks.  If you like penny stocks, you may want to add them to your penny stock watchlist.   

Let’s take a closer look at these big movers now…

Affirmative Insurance Holdings (OTCQB: AFFM)

AFFM took off like a rocket last week!

The stock soared from $1.25 on August 14th to a high of $3.60 this past Friday.  That’s a stunning move of 188% in just eight trading days.  While it couldn’t hold onto the high, AFFM finished the week at $3.25 for a one-week gain of 117%.

Now, the stock had pulled back over the past couple of days.  But it looks like a lot of investors used the weakness as a buying opportunity.  AFFM is up by 6.6% so far in morning trade.

The stock’s surging because the company recently reported its first quarterly profit in years.

Affirmative is a distributor and producer of non-standard automobile insurance policies in nine US states.  These policies provide coverage to drivers who find it difficult to get insurance due to a lack of prior insurance, age, driving record, limited financial resources, and other reasons. 

For the second quarter…

Revenue increased 41% year-over-year to $21 million on a 46% rise in total gross premiums.  Net income came in at $1.5 million compared to a loss of $5.7 million in the year ago quarter.  And earnings increased from a loss of $0.37 to a profit of $0.10 per share.

A great quarter any way you slice it.

The improved results show Affirmative is making good progress on recent actions taken on pricing, underwriting, and expense reduction.  What’s more, the company’s benefiting from favorable market conditions in key states like Texas, California, and Louisiana.

There’s no question that investors were pleased with the company’s second quarter.  But it’s too soon to tell if this is the beginning of a new trend of profitability or a one-off event.             

Celsius Holdings (OTCPINK: CELH)

Celsius Holdings is an interesting little company.  It is the creator and marketer of Celsius, a drink claimed to be “the world’s first and only negative calorie drink backed by clinical science.”  The drink is sold in supermarkets, convenience stores, health clubs, spas, and gyms throughout the US and internationally.

According to the company, Celsius is a negative calorie supplement that is clinically proven to burn calories, provide energy, reduce body fat, and enhance endurance when combined with exercise.  It comes in five ready-to-drink flavors, Orange On-the-Go powder stick packets, or a 30-serving canister. 

As you may have guessed, CELH spiked higher last week.

After closing out the prior week at 40 cents per share, CELH finished last week at 60 cents for a one-week gain of 50%.  And the stock has more than tripled in value off the April low of 19 cents per share.

That’s a stunning run in short order to say the least.

While Celsius has pulled back a bit so far this week, the stock is holding onto most of the past week’s gains.  As I write, CELH is changing hands at $0.52 per share.  This could be an opportunity to buy ahead of another leg higher.

The recent boost to Celsius’ share price follows impressive quarterly results.

For the second quarter, revenue jumped 66% year-over-year to $3 million on a big increase in international sales.  However, domestic sales were no slouch either, as all domestic segments saw double and triple digit growth during the quarter.

While the company posted a net loss of $228,000, it was much improved over the year ago quarter’s loss of $1.1 million.

Investors certainly liked the news.  They sent CELH soaring to its highest level in over three years.  We’ll have to see if the stock is able to build on these gains going forward.

Prana Biotechnology (NASDAQ: PRAN)

Prana is a development stage biotech focusing on new drugs for Alzheimer’s, Parkinson’s, and Huntington’s diseases.  The company’s leading drug candidate is PBT2, which is currently undergoing a phase 2b trial in Alzheimer’s disease and a phase 2a trial in Huntington’s disease.

Here’s the thing… PRAN soared over the past week!

In fact, the stock has been moving steadily higher since the second week of August.  After hitting a low of $3.17 on August 6th, PRAN climbed to a high of $6.24 last Friday before finishing the week at $5.83.

That’s an 84% gain in just over two weeks’ time.

And most of that gain came last week on the back of PRAN’s 41% surge.

What’s going on?

Investors have been piling into PRAN ahead of upcoming results from the phase 2a trial of PBT2 in Huntington’s disease.  Those results are expected sometime in October.  What’s more, results from the phase 2b trial in Alzheimer’s patients are expected in March 2014.

These are huge potential upside catalysts for PRAN.

Positive results would mean PRAN is on track to developing treatments for two debilitating diseases for which there are no cures and very few treatment options.  In addition, spending on Huntington’s disease drugs is projected to hit $870 million by 2018 while the Alzheimer’s drug market is already north of $10 billion annually.

With sales potential like that, it’s not hard to see why investors are excited about PRAN.

Nevertheless, PRAN is giving up some ground in recent trade.  The shares have moved back below $5 as I write.  But this could be just a quick pull back as investors rush to lock in hefty short-term profits.

If so, it may be a terrific buying opportunity.

With major catalysts fast approaching, PRAN could very well make another huge upside move in the next few weeks. 

But be careful if you trade these shares.  Penny stock biotechs are highly speculative and volatile.  If the upcoming trial data is disappointing, the stock will get crushed.  With that said, the stock would likely soar on positive results.       

Profitably Yours,

Robert Morris

Tags: , , , , , , , ,

Category: Penny Stocks

About the Author ()

Robert Morris is the editor of Penny Stock All-Stars, an investment advisory focused on discovering small-cap and micro-cap stocks that are destined to become the market’s next Blue Chips. The Wall Street veteran and small-cap stock specialist is also a regular contributor to Penny Stock Research. Every week, Robert shares his thoughts with our readers on a variety of penny stock-related topics. In addition to Penny Stock Research, Robert also writes frequently for two other free financial e-letters, ETF Trading Research and the Dynamic Wealth Report. He’s also the editor of two highly successful and popular investment advisories, Biotech SuperTrader and China Stock Insider.

Leave a Reply

Your email address will not be published.